HRP20020626B1 - Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors - Google Patents
Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptorsInfo
- Publication number
- HRP20020626B1 HRP20020626B1 HR20020626A HRP20020626A HRP20020626B1 HR P20020626 B1 HRP20020626 B1 HR P20020626B1 HR 20020626 A HR20020626 A HR 20020626A HR P20020626 A HRP20020626 A HR P20020626A HR P20020626 B1 HRP20020626 B1 HR P20020626B1
- Authority
- HR
- Croatia
- Prior art keywords
- radical
- methoxy
- phenyl
- atom
- indol
- Prior art date
Links
- 102000004136 Vasopressin Receptors Human genes 0.000 title 1
- 108090000643 Vasopressin Receptors Proteins 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- -1 trifluoromethoxy radical Chemical class 0.000 abstract 9
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 5
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- BQIKRTGTPBOIMK-UHFFFAOYSA-N [O]C[O] Chemical group [O]C[O] BQIKRTGTPBOIMK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical group C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002184 metal Chemical group 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0000957A FR2804114B1 (fr) | 2000-01-25 | 2000-01-25 | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| PCT/FR2001/000226 WO2001055130A2 (fr) | 2000-01-25 | 2001-01-24 | Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'arginine-vasopressine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20020626A2 HRP20020626A2 (en) | 2003-10-31 |
| HRP20020626B1 true HRP20020626B1 (en) | 2009-04-30 |
Family
ID=8846307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020626A HRP20020626B1 (en) | 2000-01-25 | 2002-07-24 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US6730695B2 (xx) |
| EP (1) | EP1255751B1 (xx) |
| JP (1) | JP3992498B2 (xx) |
| KR (1) | KR100689922B1 (xx) |
| CN (1) | CN1193025C (xx) |
| AR (1) | AR027263A1 (xx) |
| AT (1) | ATE269326T1 (xx) |
| AU (1) | AU778196B2 (xx) |
| BG (1) | BG65796B1 (xx) |
| BR (1) | BR0107807B1 (xx) |
| CA (1) | CA2396814C (xx) |
| CZ (1) | CZ300917B6 (xx) |
| DE (1) | DE60103853T2 (xx) |
| DK (1) | DK1255751T3 (xx) |
| EA (1) | EA004628B1 (xx) |
| EE (1) | EE04779B1 (xx) |
| ES (1) | ES2222342T3 (xx) |
| FR (1) | FR2804114B1 (xx) |
| HK (1) | HK1050900A1 (xx) |
| HR (1) | HRP20020626B1 (xx) |
| HU (1) | HU229081B1 (xx) |
| IL (2) | IL150539A0 (xx) |
| IS (1) | IS2313B (xx) |
| ME (1) | MEP17308A (xx) |
| MX (1) | MXPA02007259A (xx) |
| NO (1) | NO323607B1 (xx) |
| PL (1) | PL204160B1 (xx) |
| PT (1) | PT1255751E (xx) |
| RS (1) | RS50290B (xx) |
| SI (1) | SI1255751T1 (xx) |
| SK (1) | SK286976B6 (xx) |
| TR (1) | TR200402344T4 (xx) |
| TW (1) | TWI283672B (xx) |
| UA (1) | UA74354C2 (xx) |
| WO (1) | WO2001055130A2 (xx) |
| ZA (1) | ZA200205224B (xx) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804114B1 (fr) * | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| FR2805536B1 (fr) * | 2000-02-25 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| FR2842527B1 (fr) * | 2002-07-19 | 2005-01-28 | Sanofi Synthelabo | Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique |
| WO2005021534A1 (ja) * | 2003-08-28 | 2005-03-10 | Taisho Pharmaceutical Co., Ltd. | １，３−ジヒドロ−２ｈ−インドール−２−オン誘導体 |
| US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| US20050165082A1 (en) * | 2003-12-16 | 2005-07-28 | Wyeth | Methods of treating vasomotor symptoms |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| WO2006038119A1 (en) * | 2004-10-08 | 2006-04-13 | Warner-Lambert Company Llc | Stereoselective synthesis of n-protected alkoxy prolines |
| WO2006070742A1 (ja) * | 2004-12-27 | 2006-07-06 | Kyoto University | 麻薬性鎮痛剤の耐性形成抑制剤 |
| CA2593044A1 (en) * | 2004-12-31 | 2006-07-13 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof |
| JP5125501B2 (ja) * | 2005-01-28 | 2013-01-23 | 大正製薬株式会社 | １，３−ジヒドロ−２ｈ−インドール−２−オン化合物、及び芳香族複素環が縮合したピロリジン−２−オン化合物 |
| TW200643015A (en) * | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| CN101258134B (zh) * | 2005-03-11 | 2011-10-12 | 欧加农股份有限公司 | 2-(4-氧代-4h-喹唑啉-3-基)乙酰胺衍生物及其作为加压素v3拮抗剂的用途 |
| DE102005014904A1 (de) | 2005-03-26 | 2007-02-01 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
| WO2006100082A2 (de) * | 2005-03-24 | 2006-09-28 | Abbott Gmbh & Co. Kg | Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung |
| DE102005014936A1 (de) | 2005-03-24 | 2006-12-14 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
| AU2006255009B2 (en) | 2005-06-07 | 2011-10-27 | Pharmacopeia L.L.C. | Azinone and diazinone V3 inhibitors for depression and stress disorders |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US8048874B2 (en) * | 2005-07-19 | 2011-11-01 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| US8044079B2 (en) | 2005-12-02 | 2011-10-25 | Abbott Gmbh & Co. Kg | Substituted oxindole derivatives, medicaments containing said derivatives and use thereof |
| CN101033209B (zh) * | 2006-03-09 | 2014-08-27 | 上海医药工业研究院 | 药物中间体(2s,4r)-4-羟基-n,n-二甲基-2-吡咯烷甲酰胺的制备方法 |
| DE102006040915A1 (de) | 2006-08-26 | 2008-03-20 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
| JP5437070B2 (ja) | 2006-08-26 | 2014-03-12 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換ベンゾイミダゾロン誘導体、それを含む薬剤およびそれの使用 |
| JP5256202B2 (ja) * | 2006-09-11 | 2013-08-07 | エム・エス・ディー・オス・ベー・フェー | キナゾリノンおよびイソキノリノンアセトアミド誘導体 |
| US7427008B2 (en) * | 2006-10-25 | 2008-09-23 | Black & Decker Inc. | Depth adjusting device for a power tool |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US20100179176A1 (en) * | 2006-12-13 | 2010-07-15 | N.V. Organon | V3 antagonists for the treatment or prevention of chronic pain |
| UY30846A1 (es) * | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
| NZ586651A (en) * | 2007-12-07 | 2012-06-29 | Abbott Gmbh & Co Kg | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases |
| US8703774B2 (en) | 2007-12-07 | 2014-04-22 | AbbVie Deutschland GmbH & Co. KG | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases |
| WO2009071687A1 (de) | 2007-12-07 | 2009-06-11 | Abbott Gmbh & Co. Kg | Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
| CA2707671C (en) | 2007-12-07 | 2016-02-02 | Abbott Gmbh & Co. Kg | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases |
| WO2009083559A1 (de) | 2007-12-27 | 2009-07-09 | Abbott Gmbh & Co. Kg | Substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
| FR2927625B1 (fr) | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
| FR2930249B1 (fr) | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
| WO2009140484A1 (en) * | 2008-05-15 | 2009-11-19 | Sanofi-Aventis | Processes for preparing amorphous drug substance |
| WO2009140479A1 (en) * | 2008-05-15 | 2009-11-19 | Sanofi-Aventis | Amorphous solid dispersions |
| WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
| WO2012043791A1 (ja) | 2010-10-01 | 2012-04-05 | 大正製薬株式会社 | １，２，４-トリアゾロン誘導体 |
| MY168930A (en) | 2011-10-27 | 2019-01-09 | Taisho Pharmaceutical Co Ltd | Azole derivative |
| SG11201406182PA (en) | 2012-03-30 | 2014-10-30 | Taisho Pharmaceutical Co Ltd | Fused azole derivative |
| CN103342672B (zh) * | 2013-07-02 | 2015-12-23 | 扬州大学 | 取代吡咯烷-2-酮的新合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338755A (en) * | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
| WO1995018105A1 (fr) * | 1993-12-24 | 1995-07-06 | Sanofi | Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804114B1 (fr) * | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| FR2810320B1 (fr) * | 2000-06-19 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
-
2000
- 2000-01-25 FR FR0000957A patent/FR2804114B1/fr not_active Expired - Fee Related
-
2001
- 2001-01-19 TW TW090101300A patent/TWI283672B/zh not_active IP Right Cessation
- 2001-01-23 AR ARP010100275A patent/AR027263A1/es not_active Application Discontinuation
- 2001-01-24 EE EEP200200409A patent/EE04779B1/xx not_active IP Right Cessation
- 2001-01-24 IL IL15053901A patent/IL150539A0/xx active IP Right Grant
- 2001-01-24 TR TR2004/02344T patent/TR200402344T4/xx unknown
- 2001-01-24 DE DE60103853T patent/DE60103853T2/de not_active Expired - Lifetime
- 2001-01-24 BR BRPI0107807-0A patent/BR0107807B1/pt not_active IP Right Cessation
- 2001-01-24 WO PCT/FR2001/000226 patent/WO2001055130A2/fr active IP Right Grant
- 2001-01-24 EP EP01907685A patent/EP1255751B1/fr not_active Expired - Lifetime
- 2001-01-24 AT AT01907685T patent/ATE269326T1/de active
- 2001-01-24 CZ CZ20022497A patent/CZ300917B6/cs not_active IP Right Cessation
- 2001-01-24 RS YUP-523/02A patent/RS50290B/sr unknown
- 2001-01-24 MX MXPA02007259A patent/MXPA02007259A/es active IP Right Grant
- 2001-01-24 ES ES01907685T patent/ES2222342T3/es not_active Expired - Lifetime
- 2001-01-24 DK DK01907685T patent/DK1255751T3/da active
- 2001-01-24 SK SK1083-2002A patent/SK286976B6/sk not_active IP Right Cessation
- 2001-01-24 EA EA200200628A patent/EA004628B1/ru not_active IP Right Cessation
- 2001-01-24 CN CNB018041159A patent/CN1193025C/zh not_active Expired - Lifetime
- 2001-01-24 HU HU0204242A patent/HU229081B1/hu not_active IP Right Cessation
- 2001-01-24 AU AU35594/01A patent/AU778196B2/en not_active Ceased
- 2001-01-24 SI SI200130155T patent/SI1255751T1/xx unknown
- 2001-01-24 KR KR1020027009561A patent/KR100689922B1/ko not_active IP Right Cessation
- 2001-01-24 JP JP2001560989A patent/JP3992498B2/ja not_active Expired - Fee Related
- 2001-01-24 ME MEP-173/08A patent/MEP17308A/xx unknown
- 2001-01-24 CA CA002396814A patent/CA2396814C/en not_active Expired - Fee Related
- 2001-01-24 US US10/182,048 patent/US6730695B2/en not_active Expired - Lifetime
- 2001-01-24 PT PT01907685T patent/PT1255751E/pt unknown
- 2001-01-24 UA UA2002075477A patent/UA74354C2/uk unknown
- 2001-01-24 PL PL357553A patent/PL204160B1/pl not_active IP Right Cessation
-
2002
- 2002-06-28 IS IS6451A patent/IS2313B/is unknown
- 2002-06-28 ZA ZA200205224A patent/ZA200205224B/en unknown
- 2002-07-02 IL IL150539A patent/IL150539A/en not_active IP Right Cessation
- 2002-07-23 NO NO20023510A patent/NO323607B1/no not_active IP Right Cessation
- 2002-07-23 BG BG106947A patent/BG65796B1/bg unknown
- 2002-07-24 HR HR20020626A patent/HRP20020626B1/xx not_active IP Right Cessation
-
2003
- 2003-05-05 HK HK03103183A patent/HK1050900A1/xx not_active IP Right Cessation
-
2004
- 2004-04-29 US US10/835,209 patent/US7129240B2/en not_active Expired - Lifetime
-
2006
- 2006-08-03 US US11/462,062 patent/US7297692B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338755A (en) * | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
| WO1995018105A1 (fr) * | 1993-12-24 | 1995-07-06 | Sanofi | Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020626B1 (en) | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | |
| AR034792A1 (es) | Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica | |
| HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
| EA200401056A1 (ru) | Комбинация, содержащая производные тропана, полезные в терапии | |
| TR200400185T4 (tr) | PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri. | |
| EA200401172A1 (ru) | Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии | |
| ATE380818T1 (de) | Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose | |
| HRP20050213A2 (en) | 2,4-substituted indoles and their use as 5-ht6 modulators | |
| NO20101069L (no) | Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva | |
| HUP0400250A2 (hu) | 5-HT6 és/vagy 5-HT7 szerotonin receptorok ligandumaként alkalmazott 5-halogén-triptamin-származékok, előállításuk és alkalmazásuk gyógyszerkészítmények előállítására | |
| MXPA05007341A (es) | Derivados de 2-piperidona como agonistas de prostaglandina. | |
| DE60033964D1 (de) | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung | |
| HUP0303118A2 (hu) | Új 1,3-dihidro-2H-indolon-származékok, előállítási eljárásuk és azokat tartalmazó gyógyszerkészítmények | |
| NO952208L (no) | Amin-derivater | |
| PE20011212A1 (es) | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
| AR057464A1 (es) | Procedimiento para la preparacion de derivados de sulfonamida | |
| ATE413882T1 (de) | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren | |
| WO2002028844A1 (fr) | Dérivés thiazole ou oxazole | |
| CO5540322A2 (es) | Nuevos derivados heterociclicos que comprenden un anillo de tetrahidroisoquinolina y uso farmaceutico de los mismos | |
| HRP20030610B1 (en) | Process for the preparation of mesylates of piperazine derivatives | |
| ATE374750T1 (de) | Serotoninwiederaufnahme-inhibitoren | |
| PT1202954E (pt) | Novas aminobenzofenonas | |
| IL160874A0 (en) | 4-imidazolin-2-one derivatives | |
| FI941068A0 (fi) | Bentsoksatsiinijohdannaiset, niiden valmistus ja terapeuttinen käyttö |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: SANOFI-AVENTIS, FR |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20111222 Year of fee payment: 12 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20130125 |